With respect to tailored antithrombotics combined with hematologic treatment in the context of systemic thrombosis, the JAK-2 mutation discovery might warrant a long-standing anticoagulant or at least antiplatelet therapy, specifically in the older patients (65 years old and above), in patients with non-transient concurrent risk factors or patients with an active myeloproliferative disorder (26). This evidence concerns the gene JAK2 and Venous thrombosis.